![高級病生6次課動脈硬化講座碩士班課件_第1頁](http://file4.renrendoc.com/view/796a4d172a595dfa3dab15a7ff611892/796a4d172a595dfa3dab15a7ff6118921.gif)
![高級病生6次課動脈硬化講座碩士班課件_第2頁](http://file4.renrendoc.com/view/796a4d172a595dfa3dab15a7ff611892/796a4d172a595dfa3dab15a7ff6118922.gif)
![高級病生6次課動脈硬化講座碩士班課件_第3頁](http://file4.renrendoc.com/view/796a4d172a595dfa3dab15a7ff611892/796a4d172a595dfa3dab15a7ff6118923.gif)
![高級病生6次課動脈硬化講座碩士班課件_第4頁](http://file4.renrendoc.com/view/796a4d172a595dfa3dab15a7ff611892/796a4d172a595dfa3dab15a7ff6118924.gif)
![高級病生6次課動脈硬化講座碩士班課件_第5頁](http://file4.renrendoc.com/view/796a4d172a595dfa3dab15a7ff611892/796a4d172a595dfa3dab15a7ff6118925.gif)
版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請進(jìn)行舉報(bào)或認(rèn)領(lǐng)
文檔簡介
高級病生第6次課動脈硬化講座碩士班高級病生第6次課動脈硬化講座碩士班1“Chronicinflammatorydisorderofintimaoflargebloodvesselscharacterisedbyformationoffibrofattyplaquescalledatheroma”.Hardeningofarteries-ArteriosclerosisArteriosclerosis“Chronicinflammatorydisorder2MacrophagesT-lymphocytesAtheromatousplaqueLumenFibrouscapEndothelialcellsMacrophagesAtheromatousLumenF3AtherosclerosisLipidmetabolismimbalanceInflammationImmuno-responseAtherosclerosisLipidmetabolis4LipidmetabolismimbalanceLipidmetabolismimbalance5ClassificationoflipidsandlipoproteinsClassificationoflipidsandl6CharacteristicsoflipoproteinsCharacteristicsoflipoprotein7DigestionandmetabolismofdietaryfatDigestionandmetabolismofdi8HDLmetabolismandreversecholesteroltransportHDLmetabolismandreversecho9Cholesteroleffluxandreversecholesterol
transportismodulatedbytworeceptorsCholesteroleffluxandreverse10PPARαactivatorsinducecholesterolefflux
andreversecholesteroltransportPPARαactivatorsinducecholes11HDLmetabolism:
5keygenes
HDLmetabolism:
5keygenes12PPARα:apoA-l,apoA-ll,LPL,
ABCA-1andSR-BIexpressionPPARα:apoA-l,apoA-ll,LPL,13PPARaactivatorsinducecholesterolefflux
fromhumanmacrophagesPPARaactivatorsinducecholes14CLA-1/SR-BIproteinmaypromotecholesterol
removalfromperipheralcellsCLA-1/SR-BIproteinmaypromot15CLA-1expressionisregulatedbyPPARαactivators
indifferentiatedhumanmacrophagesCLA-1expressionisregulated16PPARαactivatorsinducecholesterolefflux
andreversecholesteroltransportPPARαactivatorsinducecholes17LDLLDL18Theearlylesion:modifiedlipoproteinsandfoamcellformationTheearlylesion:modifiedlip19ClassesofScavengerReceptorsPluddemannetal.Methods43(2007)207-217ClassesofScavengerReceptors20TheScavengerReceptorFamiliesformodifiedLDLCollagen-likeSRCRSR-AMARCOClassACD36SR-B1immunodominantClassBEGF-likeSR-ECLOX-1Lectin-likeSR-PSOXChemokine-domainMucin-stalkTheScavengerReceptorFamilie21高級病生6次課動脈硬化講座碩士班課件22ThemacrophageasaninflammatorymediatorThemacrophageasaninflammat23StatinsinducePPARαactivityStatinsinducePPARαactivity24MacrophagesT-lymphocytesAtheromatousplaqueLumenFibrouscapEndothelialcellsMacrophagesAtheromatousLumenF25InflammationInflammation26RoleofmacrophagesMCSFinducesmonocytesenteringlesionto differentiateintomacrophagesMacrophagedifferentiationassociatedwithTLRs andscavengerreceptorsMCSF/apoEKOshowsreducedatherosclerosisScavengerreceptorsbindbacterialendotoxins, apoptoticcellsandoxLDLSR/apoEKOsshowreducedatherosclerosisRoleofmacrophagesMCSFindu27Toll-likeGENESIL-1RTNF-RIFN-gRIRFNFkBMAP
KINASEJAK/STATInflammation,Anti-MicrobialResponse,Apoptosis,…Toll-likeGENESIL-1RTNF-RIFN-gR28TLRreceptorsandatherosclerosis10familymembersRecognizepathogenassociatedmolecularpatterns (e.g.LPS,dsRNA)aswellasoxLDL,HSP60etc.Initiatesignalingcascadesleadingtoproductionof inflammatorycytokines,proteases,reactiveoxygen speciesInadditiontomacrophages,expressedbydendritic cells,mastcells,endothelialcellsTLRreceptorsandatherosclero292004Science3031481-1482InflammatorycytokinesToll-likeReceptors(TLRs)2004Science3031481-1482Infl30nLDLmmLDLoxLDL15-LO,Fe2+Cu2+Contd.ox.?CD14?TLR4CD36InflammationFoamcellsAirox.nLDLmmLDLoxLDL15-LO,Fe2+Cu2+C31PAFRGPCRsCD36SR-ATLRsCRPNaturalIgMsBindinganduptakeCytokinesCo-stimulatorymoleculesMDALPCPAF-likelipidsoxLDLOxidizedphospholipidsExposedPCheadgroupsLipidmediatorsComplementproteinsChemokinesInflammatorycellrecruitmentComplementactivationAdaptiveimmuneresponseFoamcellformationPAFRGPCRsCD36SR-ATLRsCRPNatura32TLRsCytokinesCo-stimulatorymoleculesAdaptiveimmuneresponseMyD88AdjuvantsAutoimmuneligandsLipidligandsTregoxLDLCD1LipidantigensAtheroprotectiveimmunity?TLRsCytokinesCo-stimulatorymo33mmLDLPCMCMyD88TLR4LPSoxPLTLR4[61]mmLDL[35,36]AdhesionmoleculesCD14/TLR4[63,64]MyD88Inflammatorycytokines[60]CD36TLR2/TLR6oxLDLApoptoticcellsBacterialdiacylatedlipopeptidesandlipoteichoicacidTLR2[66][65]TRIFIRF-3Cholesterolefflux[74]TLR1/TLR2EndogenousligandBacterialtriacylatedlipopeptide[26][26]”Infectiousburden”ExogenousligandsTLR4TLR4[23,24]LPSoxPLImmunologicalpriming[86]TLR4Co-stimulatorymolecules[51][20]MacrophagefoamcellECMonocyterecuitmentInflammatorycytokinesLipiduptakeBj?rkbacka(2006)CurrOpinLipidol17:527-53mmLDLPCMCMyD88TLR4LPSoxPLTLR4[34InnateimmunityN-fMetpeptidesChemokinesLipidmediatorsMyD88BacterialandviralPAMPsGPCRsTLRsAntibodyopsonizationoxLDLIncreasedintegrinavidityCytoskeletalchangesRespiratoryburstPhagocytosisAdhesiontoendotheliumMigrationintotissuesKillingofmicrobeROIsCellularresponseFunctionaloutcomeNaturalIgMsCRP,SAPBacterialphosphoryl-cholineComplementactivationComplementopsonizationScRsMannosereceptorFcRCRsMicrobialglyco-proteins/lipids(mannose)AntigenpresentationCytokinesandchemokinesreleasedC5a,C3a,C4aSignalingInnateimmunityN-fMetpeptides35Immuno-responseImmuno-response36ReducedatherosclerosisinMyD88nullmiceBj?rkbackaetal.(2004)Nat.Med.10:416-421ReducedatherosclerosisinMyD37TLRsandatherosclerosisCD14TLR4MD2MyD88TRAMTRIFMal/TirapTLR1TLR2TLR6TLR2TLR4MyD88MyD88Bj?rkbackaetal.Nat.Med.(2004)10:416-421Michelsenetal.PNAS(2004)101:10679-10684Mullicketal.JCI(2005)115:3149-3156CD36Hoebeetal(2005)Nature433:523-527TLRsandatherosclerosisCD14TL38高級病生6次課動脈硬化講座碩士班課件39高級病生6次課動脈硬化講座碩士班課件40高級病生6次課動脈硬化講座碩士班課件41WhydoesoxidizedLDLbecomeimmunogenic?FragmentationofapoB-100OxidationofphospholipidsFormationofcovalentaldehyde(MDA)andaminoacidadductsWhydoesoxidizedLDLbecomei42高級病生6次課動脈硬化講座碩士班課件43HowDoesImmunizationWithOxidized
LDLAffectAtherosclerosis?Reduceddevelopmentofatherosclerosisinrabbits(PalinskietalPNAS1995,AmelietalATVB1996)ReduceddevelopmentofatherosclerosisinapoEdeficientmice(GeorgeetalAtherosclerosis1998,FreigangetalATVB1998,ZhouetalATVB2001)HowDoesImmunizationWithOxi44Isitpossibletoproduceavaccineagainstatherosclerosis?WhatstructuresinoxidizedLDLarerecognizedbytheimmunesystem?Aretheseimmuneresponsesassociatedwithcardiovasculardiseaseinhumans?Canprotectiveimmuneresponsesbeselectivelyactivatedbyavaccine?Canantibodiesbeuseddirectlytotreatatherosclerosis?Isitpossibletoproduceava45CharacterizationofepitopesinoxidizedLDLbyalibraryofpeptideELISAs
302peptides,correspondingtothecompleteaminoacidsequenceofApoB-100Eachpeptideconsistsof20aminoacidswith5aminoacidsoverlapModificationbymalondialdehyde(MDA)Characterizationofepitopesi46ActiveimmunizationofapoEnullmicewithapoB-100peptidesequencesImmunizationwith100mgpeptidesat6,9and11weeksofageusingAlumasadjuvantHighcholesteroldietat10weeksofageAtherosclerosisassessedbyOilRedOstainingofthedescendingaortaat25weeksofageActiveimmunizationofapoEn47EffectofoxidizedLDLpeptidevaccinesonatherosclerosisinmice%atherosclerosisP<0.01P<0.00500,050,10,150,20,250,3ControlPeptide45Peptide210Peptide240FredriksonGNetalEffectofoxidizedLDLpeptide48EffectofimmunizationwithMDA-apoB-100peptide45onspecificIgM,IgG,IgG1(Th2)andIgG2a(Th1)inapoEnullmice*p<0.05,***p<0.005012CarrierIgM
IgGIgM
IgGFragment
I***FredriksonGNetal,Autoimmunity2005.EffectofimmunizationwithMD49ImmunizationusingMDA-apoB-100peptidesinmiceReductionofatherosclerosisbyupto70%RemainingplaquescontainmorecollagenandlessmacrophagesIncreaseinIgGbutnotinIgMSwitchfromTh1toTh2-specificIgGNosignificanteffectsonplasmalipidsImmunizationusingMDA-apoB-150PassiveimmunizationstrategyHumanIgG1againstpeptides45and210wereproducedthroughscreeningofasinglechainantibodyfragmentlibraryandsubsequentcloningintoapcDNA3vector
ApoEknockoutmiceweregivenhighcholesteroldietfrom6weeksofageTreatedwith0.5mgantibodyat21,22and23weeksofageandsacrificedtwoweekslaterEffectsassessedbyOROstainingofdescendingaorta,TrichromeMassonstainingandmacrophageimmunostainingofsubvalvularplaquesPassiveimmunizationstrategyH51EffectofpassiveimmunizationwithrecombinanthumanIgGagainstpeptide45onearlyatherosclerosisinmiceSchiopuetal,Circulation2004Effectofpassiveimmunization52Regressionofaortic
溫馨提示
- 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫網(wǎng)僅提供信息存儲空間,僅對用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時也不承擔(dān)用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。
最新文檔
- 2025年高、低能校正磁鐵合作協(xié)議書
- 部編初中數(shù)學(xué)八年級下學(xué)期開學(xué)考試卷
- 2025年交配電設(shè)備設(shè)施委托管理協(xié)議(2篇)
- 2025年產(chǎn)權(quán)房屋買賣合同經(jīng)典版(三篇)
- 2025年產(chǎn)品商標(biāo)設(shè)計(jì)委托合同模板(三篇)
- 2025年產(chǎn)品采購協(xié)作服務(wù)協(xié)議(2篇)
- 2025年亮化工程施工承包合同經(jīng)典版(三篇)
- 2025年中班幼兒園教師個人工作心得體會模版(4篇)
- 2025年產(chǎn)品試用協(xié)議范例(2篇)
- 2025年個人房屋裝修委托書合同(2篇)
- 招聘專員轉(zhuǎn)正述職報(bào)告
- “一帶一路”背景下的西安市文化旅游外宣翻譯研究-基于生態(tài)翻譯學(xué)理論
- 2024年江蘇省昆山市六校中考聯(lián)考(一模)化學(xué)試題
- 大學(xué)生文學(xué)常識知識競賽考試題庫500題(含答案)
- 國家電網(wǎng)智能化規(guī)劃總報(bào)告
- 邢臺市橋西區(qū)2024年事業(yè)單位考試《公共基礎(chǔ)知識》全真模擬試題含解析
- 太原頭腦外賣營銷方案
- 2023年寧夏中考物理試題(附答案)
- JBT 7041.1-2023 液壓泵 第1部分:葉片泵 (正式版)
- 2024年浙江首考英語聽力原文解惑課件
- 國家基層糖尿病防治管理指南(2022)更新要點(diǎn)解讀-1074177503
評論
0/150
提交評論